Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
AbbVie is conducting a Phase 1/2 study titled A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2 Inhibitor ABBV-453 Given as Monotherapy or in Combination With Antimyeloma Regimens in Subjects With Multiple Myeloma. The study aims to assess the safety and efficacy of ABBV-453, alone or with other antimyeloma agents, in treating relapsed/refractory multiple myeloma (R/R MM). This research is significant as it explores new treatment avenues for a challenging condition.
The intervention involves the investigational drug ABBV-453, a BCL-2 inhibitor, administered orally. It is tested alone or in combination with daratumumab, dexamethasone, and pomalidomide, aiming to determine the optimal dosage and improve treatment outcomes for R/R MM.
The study employs a randomized, sequential intervention model with no masking, focusing on treatment as its primary purpose. This design allows for a structured evaluation of ABBV-453’s safety and efficacy in different combinations.
The study began on July 23, 2025, with an estimated primary completion date yet to be announced. The last update was submitted on August 1, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
This study could significantly impact AbbVie’s stock performance by potentially introducing a new treatment for multiple myeloma, enhancing investor sentiment. It also places AbbVie in a competitive position within the pharmaceutical industry, especially in the oncology sector.
The study is currently recruiting, with further details available on the ClinicalTrials portal.